Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Padlock Therapeutics Inc.

Division of Bristol-Myers Squibb Co.
www.padlocktherapeutics.com

Latest From Padlock Therapeutics Inc.

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.
Financing StartUps and SMEs

Start-Up Obsidian Gets $49.5m To Determine How And When To Activate CAR-T Cells

Obsidian CEO Michael Gilman described the company's technology – which allows CAR-T cells and other therapies to be activated by available small molecule drugs – as being able to modulate the effective yet toxic therapies by dialing down, turning up or shutting off the treatments as needed.

Financing StartUps and SMEs

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date

Private Company Edition: Life science firms in J&J's JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.

StartUps and SMEs Financing

Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund

Public biopharma offerings gained momentum, including four IPOs during the last week of June, as US investors looked kindly on the sector ahead of July 4 celebrations. Also, VC investment continued unabated as Atlas Venture closed a new $350m fund.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Bristol-Myers Squibb Co.
  • Senior Management
  • Michael Gilman, PhD, CEO
    Rajesh Devraj, PhD, CSO
  • Contact Info
  • Padlock Therapeutics Inc.
    Phone: (978) 381-9601
    200 Cambridge Pk. Dr.
    Cambridge, MA 02140
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register